article Open AccessTop 1% cited

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

BMC Cancer · 2008 · Vol. 8(1) · pp. 17–17

Joshua Z. Press✉(University of British Columbia)Alessandro De Luca(University of British Columbia)Niki Boyd(University of British Columbia)Sean Young(University of British Columbia)Armelle A. Troussard(University of British Columbia)Yolanda Ridge(BC Cancer Agency)Pardeep Kaurah(BC Cancer Agency)Steve E. Kalloger(Vancouver General Hospital)Katherine A Blood(University of British Columbia)Margaret J. Smith(The Royal Melbourne Hospital)Paul T. Spellman(University of California, San Francisco)Yuker WangDianne Miller(University of British Columbia)Doug Horsman(The Royal Melbourne Hospital)Malek FahamC. Blake Gilks(Vancouver General Hospital)Joe W. Gray(Lawrence Berkeley National Laboratory)David G. Huntsman(Vancouver General Hospital)

View via DOI Full-text PDF

Abstract

High grade serous carcinomas can be subclassified into three groups: BRCA1 loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct molecular alterations involving the PI3K/AKT and p53 pathways.

Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer Cancer Genomics and DiagnosticsSerous fluidLoss of heterozygosityEpigeneticsPTENCancer researchBiologyDNA methylationGermline mutationGermlineSomatic cell

MeSH terms

Base SequenceFemaleHumansImmunohistochemistryNuclear ProteinsOvarian NeoplasmsRNA, MessengerTranscription FactorsGenome, HumanGene Expression Regulation, NeoplasticTumor Suppressor Protein p53Gene DeletionBRCA1 ProteinEpigenesis, GeneticPTEN Phosphohydrolase